

1 An integrated computational and experimental study to elucidate

2 *Staphylococcus aureus* metabolism

3  
4 Mohammad Mazharul Islam<sup>1</sup>, Vinai C. Thomas<sup>2</sup>, Matthew Van Beek<sup>1</sup>, Jong-Sam Ahn<sup>2</sup>,  
5 Abdulelah A. Alqarzaee<sup>2</sup>, Chunyi Zhou<sup>2</sup>, Paul D. Fey<sup>2</sup>, Kenneth W. Bayles<sup>2</sup>, and Rajib Saha<sup>1\*</sup>

6  
7 <sup>1</sup>Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln

8 <sup>2</sup>Center for Staphylococcal Research, Department of Pathology and Microbiology, University of  
9 Nebraska Medical Center

10  
11 **Running title:** Integrated study of *S. aureus* metabolism

12  
13  
14 \*Corresponding author:

15 Rajib Saha

16 Assistant Professor

17 Chemical and Biomolecular Engineering

18 University of Nebraska-Lincoln

19 Lincoln, NE-68588, USA

20 Email: [rsaha2@unl.edu](mailto:rsaha2@unl.edu)

21

22

## 23 **Abstract**

24 *Staphylococcus aureus* is a metabolically versatile pathogen that colonizes nearly all organs of  
25 the human body. A detailed and comprehensive knowledge of staphylococcal metabolism is  
26 essential to understanding its pathogenesis. To this end, we have reconstructed and  
27 experimentally validated an updated and enhanced genome-scale metabolic model of *S. aureus*  
28 USA300\_FPR3757. The model combined genome annotation data, reaction stoichiometry, and  
29 regulation information from biochemical databases and previous strain-specific models.  
30 Reactions in the model were checked and fixed to ensure chemical balance and thermodynamic  
31 consistency. To further refine the model, growth assessment of 1920 non-essential mutants from  
32 the Nebraska Transposon Mutant Library was performed and metabolite excretion profiles of  
33 important mutants in carbon and nitrogen metabolism were determined. The growth and no-  
34 growth inconsistencies between the model predictions and *in vivo* essentiality data were resolved  
35 using extensive manual curation based on optimization-based reconciliation algorithms. Upon  
36 intensive curation and refinements, the model contains 840 metabolic genes, 1442 metabolites,  
37 and 1566 reactions including transport and exchange reactions. To improve the accuracy and  
38 predictability of the model to environmental changes, condition-specific regulation information  
39 curated from the existing knowledgebase was incorporated. These critical additions improved the  
40 model performance significantly in capturing gene essentiality, substrate utilization, and  
41 metabolite production capabilities and increased the ability to generate model-based discoveries  
42 of therapeutic significance. Use of this highly curated model will enhance the functional utility  
43 of omics data and, therefore, serve as a resource to support future investigations of *S. aureus* and  
44 to augment staphylococcal research worldwide.

45

46 Keywords: *Staphylococcus aureus*, genome-scale metabolic model

## 47 Introduction

48 *S. aureus* is a versatile human pathogen that has emerged as one of the most successful infectious  
49 agents of recent times, affecting approximately 20% of the world's population<sup>1-3</sup>. The incidence  
50 of methicillin resistance at low fitness cost has significantly contributed to the rise in  
51 community-associated methicillin resistant *S. aureus* (CA-MRSA) infections, which  
52 significantly limit therapeutic options and increase rates of mortality, morbidity and costs  
53 associated with its treatment<sup>1,4,5</sup>. This threat to human health has resulted in a steady interest and  
54 focus on understanding how staphylococcal metabolism relates to antibiotic resistance and  
55 pathogenesis. A number of studies have attempted to explore the metabolic aspects of  
56 antimicrobial functionality of MRSA, including nitric oxide metabolism, oxidative stress, carbon  
57 overflow metabolism, redox imbalance etc.<sup>6-11</sup>. However, a complete mechanistic understanding  
58 of staphylococcal metabolism is still missing, making the identification of systematic therapeutic  
59 targets challenging.

60

61 The increase in knowledge of macromolecular structures, availability of numerous biochemical  
62 database resources, advances in high-throughput genome sequencing, and increase in  
63 computational efficiency have accelerated the use of *in silico* methods for metabolic model  
64 development and analysis, strain design, therapeutic target discovery, and drug development<sup>12-17</sup>.

65 There have been a number of attempts to reconstruct the metabolism of multiple strains of *S.*  
66 *aureus* using semi-automated methods<sup>18-22</sup>. However, the absence of organism-specific  
67 metabolic functions and the inclusion of genes without any specified metabolic functions still  
68 limit the utility of these models. These models need to be continually refined and updated to

69 accurately predict biological phenotypes by addressing these issues as well as by reducing  
70 metabolic network gaps, elemental imbalance, and missing physiological information. Since the  
71 predictive genome-scale metabolic models of several microorganisms were useful in performing  
72 *in silico* gene essentiality and synthetic lethality analyses and yielded promising results in  
73 pinpointing metabolic bottlenecks and potential drug targets<sup>14,23-26</sup>, the potential for accurately  
74 modeling *S. aureus* metabolism is immense. To this end, Seif *et al* recently developed an updated  
75 genome-scale model of *S. aureus* strain JE2, incorporated 3D protein structures, evaluated gene  
76 essentiality predictions against experimental physiological data, and assessed flux distributions  
77 in different media types<sup>21</sup>. Although their model was informed by multilevel omics data and a  
78 significant step toward deciphering the metabolic differences of this organism under different  
79 environmental conditions, it could further be improved by incorporating the latest annotation  
80 information, reducing the inconsistency in gene essentiality predictions, and removing spurious  
81 metabolic functionalities.

82

83 Several other studies have been dedicated to elucidating the metabolic aspects of staphylococcal  
84 virulence and to pinpoint the key metabolic “hubs” in carbon and nitrogen metabolism<sup>11,27-32</sup>.  
85 However, a majority of these studies were focused on specific segments of staphylococcal  
86 metabolism and overlooked a system-wide inter-dependence that drives fitness, metabolic  
87 robustness, virulence, and antimicrobial resistance. Hence, a holistic approach of *in silico*  
88 genome-scale modeling and *in vivo* experimentation is crucial for gaining an improved  
89 mechanistic understanding of staphylococcal metabolism and, thereby, facilitating the  
90 development of novel therapeutic strategies to combat staphylococcal infections.

91

92 In this study, a comprehensive genome-scale metabolic model of *S. aureus* USA300\_FPR3757  
93 was reconstructed using annotation information from biochemical databases<sup>33,34</sup> and previous  
94 strain-specific models<sup>19,20,34</sup> and validated through experimental observations and published  
95 phenotypic data. The model underwent extensive manual curation to ensure chemical and charge  
96 balance, thermodynamic consistency, and biomass precursors production. To test and inform the  
97 model, the fitness level of 1920 mutants from Nebraska Transposon Mutant Library (NTML)<sup>35</sup>  
98 was assessed through an elaborate growth experiment and the metabolite excretion profiles of  
99 eight important mutants distributed across several pathways of the carbon and nitrogen  
100 metabolism were measured. The growth phenotyping results of the NTML mutants were utilized  
101 via GrowMatch procedure<sup>36</sup> to reconcile *in silico* vs. *in vivo* growth inconsistencies. Upon  
102 incorporating conditional regulations in the model gleaned from existing ‘omics’ datasets<sup>30,37,38</sup>,  
103 the predictive capability of the model in terms of gene essentiality and metabolite excretions in  
104 different environmental conditions was further improved. Furthermore, the growth predictions  
105 from the model on 69 different carbon sources were validated against existing growth  
106 experiment<sup>21</sup>. Overall, this model is extensively tested by multiple available and newly-  
107 developed experimental datasets on staphylococcal metabolism and subsequently refined to pave  
108 a way forward to advance system-wide analysis of fitness and virulence.

109

## 110 **Results**

### 111 **Reconstruction of an updated model of *S. aureus* metabolism**

#### 112 *Preliminary reconstruction utilizing the existing knowledge base*

113 A collection of 1511 metabolic reactions obtained from a consensus of recently published strain-  
114 specific models<sup>19,21</sup> was assembled into a preliminary model of *S. aureus*. Out of 842 genes in

115 the latest strain-specific USA300\_FPR3757\_uid58555 model by Bosi *et al.*<sup>19</sup>, 109 did not have  
116 any reactions associated with them, which were not included in our model at this stage. Checking  
117 reactions from the *S. aureus* N315 model iSB619<sup>20</sup> against the annotations of strain  
118 USA300\_FPR3757 in the KEGG database<sup>39</sup> resulted in the inclusion of seven unique reactions to  
119 the preliminary model. In addition, every metabolic function in the model was verified for  
120 correct gene annotations in the NCBI, KEGG, and UniProt databases and published  
121 resources<sup>19,39-42</sup> to amend the model with 38 metabolic reactions and annotate 75 additional  
122 reactions with correct Gene-Protein-Reaction (GPR) rules.

123

124 These amendments resulted in a preliminary model that contained 833 metabolic genes  
125 catalyzing 1556 reactions involving 1440 metabolites. This model included reactions for central  
126 carbon metabolism, secondary biosynthesis pathway, energy and cofactor metabolism, lipid  
127 synthesis, elongation and degradation, nucleotide metabolism, amino acid biosynthesis and  
128 degradation. All the existing metabolic reconstructions of *S. aureus*<sup>19,20,22</sup>, including the most  
129 recently published model<sup>21</sup>, used a biomass equation similar to the closely-related organisms  
130 *Bacillus subtilis*<sup>43</sup> and *Escherichia coli*<sup>44</sup>, with additional adjustments to accommodate lipid  
131 compositions. However, *S. aureus* lacks an identifiable polyamine biosynthetic pathway and  
132 therefore cannot produce putrescine<sup>28,45</sup>. Therefore, putrescine was removed from the biomass  
133 equation adopted from Bosi *et al.*<sup>19</sup> in the current study. Growth condition was set to glucose  
134 minimal media with other essential nutrients (see Supplementary Table 1 for details).

135

136 *Model curation to ensure chemical balance and thermodynamic consistency*

137 The preliminary reconstruction underwent extensive manual curation steps as outlined in the  
138 methods section. In total, 197 reactions (excluding the biomass reaction, demand, sink, and  
139 exchange reactions) were found to be imbalanced in terms of proton, carbon, nitrogen, oxygen or  
140 sulfur. Most of these reactions (*i.e.*, 182 reactions) were fixed for proton imbalance and four  
141 reactions were fixed for imbalance in other elements (see Supplementary Table 2 for details).  
142 Nonetheless, a few mass- and charge-imbalanced reactions remained in the model, primarily due  
143 to the presence of macromolecules with unspecified “R”-groups and gaps in knowledge about  
144 correct reaction mechanisms. These remaining reaction imbalances are common in published  
145 genome-scale metabolic models<sup>46</sup> and given that the overall stoichiometry of the reactions  
146 involving these macromolecules is correct, these imbalances do not significantly affect the  
147 performance of the model.

148  
149 In addition to charge and elemental imbalances, the preliminary model had 291 reaction fluxes  
150 unnecessarily hitting the upper or lower bounds during a Flux Variability Analysis (FVA) when  
151 no nutrients were provided (see Methods section). Also, the inconsistent dissipation of ATP,  
152 which was persistent in earlier models<sup>19,21</sup>, also existed in the preliminary reconstruction. These  
153 two phenomena are observed when the reaction network contains thermodynamically infeasible  
154 cycles (as defined in the Methods section)<sup>47</sup>. To resolve these cycles, 27 reactions were made  
155 irreversible and two reactions were reversed in directionality based on available thermodynamic  
156 information and literature evidence (details in Supplementary Table 3). Furthermore, 66  
157 reactions were turned off either due to their improper annotations or to remove lumped or  
158 duplicate reactions from the model. For example, the irreversible duplicates for several reactions  
159 including acetolactate synthase, aconitase, phosphoribosylaminoimidazole carboxylase, alcohol-

160 NAD oxidoreductase, arginine deiminase, D-ribitol-5-phosphate NAD 2-oxidoreductase,  
161 glycerate dehydrogenase, methionine synthase, and ribokinase were removed. Also, based on  
162 available cofactor specificity information, reactions such as cytidine kinase (GTP), glycerol-3-  
163 phosphate dehydrogenase (NAD), guanylate kinase (GMP:dATP), and homoserine  
164 dehydrogenase (NADH) were turned off to ensure correct cofactor usage in these reactions.  
165 Reactions involved in polyamine synthesis and degradation were removed due to the lack of  
166 convincing evidence of polyamine functionality in *S. aureus* USA300\_FPR3757<sup>28,45</sup>. After these  
167 manual curation steps, the number of unbounded reactions (reaction fluxes hitting either the  
168 upper or the lower bound without any nutrient uptake) was reduced to seven. The annotation of  
169 *S. aureus* USA300\_FPR3757 genome in the KEGG database was next used to bridge several  
170 network gaps in the model. At this stage, the model contained 553 blocked reactions compared to  
171 784 in the preliminary reconstruction. While this was a significant improvement, the model still  
172 contained a greater number of blocked reactions than other similar-sized models<sup>21</sup>. The blocked  
173 reactions were not removed at the current stage because they contained proper gene annotation  
174 information but either their terminal dead-end metabolite was beyond the scope of the model or  
175 no convincing evidence (*e.g.*, high-score annotations) for filling the gap was available. A  
176 detailed list of the corrections and additions/removals made is given in Supplementary Table 3.  
177 The model reconstruction process, pathway distribution, and comparative model statistics are  
178 shown in Figure 1. The model is available in systems biology markup language format in  
179 Supplementary Data 1.

180

181 **Figure 1:** (a) The schematic of the reconstruction and curation process for *iSA840*, (b) pathway  
182 distribution of metabolic functions, (c) overlap of functionalities, and (d) comparison of model statistics  
183 with recent *S. aureus* metabolic models.



184

185 **Identifying essential genes from existing knowledgebase**

186 We next evaluated the growth profiles of the viable *S. aureus* mutants from the NTML<sup>35</sup>. The  
187 variation of wild-type growth among the 384-well plates in the experiment was statistically  
188 insignificant based on z-score (see Supplementary Table 4 for detailed calculations). Out of the  
189 1920 mutants studied, there were 154 genes whose mutations reduced growth by 10% relative to  
190 the wild-type strain and 21 mutations reduced the growth between 30% and 80% compared to  
191 the wild-type value. Out of all the genes from the NTML library, 41 genes were reported to be  
192 essential in other recent studies<sup>18,48-52</sup>, whereas only 11 of them showed any significant growth  
193 inhibition (more than a standard deviation from the average wild-type growth rate) in the current  
194 study (see Supplementary Table 4 for details). Therefore, the set of essential genes was a  
195 consensus of multiple literature sources<sup>18,48-52</sup> and our current experimental study (see Methods  
196 and Supplementary Text S1 for details). Briefly, transposon mutagenesis followed by growth  
197 experiments by Valentino *et al.*<sup>49</sup> and Chadhuri *et al.*<sup>51</sup> identified 426 and 351 essential genes,  
198 respectively. Since the disagreement regarding gene essentiality was persistent among these  
199 datasets, the common essential gene (comprising 319 genes) set from these two transposon  
200 mutagenesis experiment was considered to be essential, which also agreed with multiple  
201 previous growth experiments<sup>18,50,52</sup>. Later, Santiago *et al.*<sup>48</sup> demonstrated that gene essentiality  
202 derived from transposon libraries can be affected by the high temperatures used to remove the  
203 plasmid delivery vehicle and also by the polar effect in disrupting expression of essential genes  
204 in the vicinity of a non-essential gene. Therefore, following their results, these false positive  
205 genes (30 in total) were excluded from the essential gene list. Finally, for the modeling purpose,  
206 only the 167 metabolic genes (excluding non-metabolic genes) present in the model were

207 considered to be the core set of essential genes in the current study (see Supplementary Table 5  
208 for the full list of the essential genes).

209

### 210 **Model refinement to reconcile growth and no-growth inconsistencies**

211 Comparison of essential and non-essential genes between the experimental (*in vivo*) and model-  
212 based (*in silico*) gene essentiality analysis (see Methods section for details) show that there exists  
213 a significant mismatch between these two sets of results (Figure 2a). Correct model predictions  
214 for non-essential and essential genes are denoted by GG and NGNG, while wrong model  
215 predictions for non-essential and essential genes are denoted by NGG and GNG, respectively in  
216 which the first of the two terms (“G” or “NG”) corresponds to *in silico* and the second term  
217 refers to *in vivo* observations. An optimization-based procedure called Growmatch was used to  
218 reconcile the GNG inconsistencies by suppressing spurious functionalities and the NGG  
219 inconsistencies by adding miss-annotated functionalities to the model<sup>36</sup>. The overall impact of  
220 applying Growmatch is shown in Figure 2b. The specificity increased from 52% to 60.5%, the  
221 sensitivity increased from 87% to 89%, and the false viability rate decreased from 48% to 39.5%.  
222 To resolve the NGG inconsistencies, metabolic functions were added from the *E. coli* iAF1260<sup>44</sup>  
223 and *B. subtilis*<sup>43</sup> metabolic models as well as the Modelseed database<sup>34</sup>. A total of five reactions  
224 were added to the model and three reactions were allowed to go in the reverse direction based on  
225 literature evidence or thermodynamic information (detailed procedure outlined in Supplementary  
226 Information 1), which reduced the number of NGGs by 12. Model predictions of essential genes  
227 were further improved upon the removal of spurious metabolic functions. To this end, six  
228 reactions that did not have either any gene associated with them (orphan reactions) or proper  
229 gene annotation, were removed from the model, resulting in an 18% reduction in GNGs. 81 of

230 the GrowMatch predicted resolution strategies were not accepted because they resulted in  
231 conflicts with correct growth (GG) and no-growth (NGNG) predictions in the model. The details  
232 of the GrowMatch results are presented in Supplementary Table 5. Two example case studies for  
233 NGG and GNG inconsistency reconciliation process by GrowMatch are presented in the next  
234 section.

235

236 **Figure 2:** GNG table (a) before and (b) after reconciliation of growth-no growth inconsistency by  
237 GrowMatch procedure. Specificity =  $\#NGNG/(\#NGNG + \#GNG)$ , sensitivity or true viable rate (TVR) =  
238  $\#GG/(\#GG + \#NGG)$  and false viable rate (FVR) =  $\#GNG/(\#GNG + \#NGNG)$ , (c) a case study of NGG  
239 inconsistency and the corresponding Growmatch solution, and (d) a case study of GNG inconsistency and  
240 the corresponding Growmatch solution.

241

#### 242 *Case studies for reconciliation of NGG and GNG inconsistencies*

243 The deletion of aspartate transaminase appeared to be lethal by the model prediction, whereas it  
244 was non-essential *in vivo*, making it an NGG gene (the solid blue line in Figure 2c). The addition  
245 of L-aspartase (dashed blue line in Figure 2c) rescues the growth of an aspartate transaminase  
246 deletion mutant by creating another route to generate L-aspartate, which was characterized other  
247 closely related bacteria including *E. coli* and *B. subtilis*<sup>53-55</sup>. On the other hand, the Pentose  
248 Phosphate Pathway contained a GNG inconsistency, in which there were erroneous metabolic  
249 functions present in the model (Figure 2d). For example, glucose-6-phosphate isomerase and  
250 ribulose phosphate 3 epimerase are both essential genes (green highlighted genes in Figure 2d) in  
251 *S. aureus*, while they were predicted to be nonessential by the model. The reason was the  
252 presence of an alternate pathway to convert glucose-6-phosphate (G6P) to ribulose-5-phosphate  
253 (Ru5P) in the model. Since literature and database searches failed to identify the presence of

254 phospho-glucono lactonase in *S. aureus*, it was removed, and the model was made consistent  
255 with experimental essentiality prediction of glucose-6-phosphate isomerase and ribulose  
256 phosphate-3-epimerase genes.

257

### 258 **Model-driven integrated study**

259 An automated procedure like GrowMatch can significantly improve the gene essentiality  
260 predictions in the model. However, without extensive validation against experimental data and  
261 manual curations, it is difficult to obtain biologically significant and meaningful prediction  
262 capability from the model. Hence, the model was validated against multiple experimental  
263 observations from previous studies and results obtained in the current work for further  
264 refinements.

265

### 266 *Incorporation of conditional regulation to enhance mutant growth predictions*

267 The essentiality predictions for 29 amino acid catabolic pathway genes in the model was  
268 validated against the mutant growth phenotypes evaluated in a previous study<sup>29</sup>. The mutants  
269 were grown in a chemically defined medium (CDM) supplemented with 18 amino acids but  
270 lacking glucose. It was found that 11 of the mutations did not cause any growth defect, while 11  
271 mutations caused intermediate growth defect and seven mutations were lethal. It was found that  
272 the model failed to recapitulate growth phenotype for nine (*ald1/ald2*- aldehyde dehydrogenase,  
273 *aspA*- aspartate aminotransferase, *gltA*- citrate synthase, *sdhA*- succinate dehydrogenase,  
274 *sdaAA/sdaAB*- serine dehydratase, *ansA*- asparaginase, *arcA1/arcA2*- arginine deiminase, and  
275 *rocF*- arginase) out of the 29 mutants, which warranted further investigation and refinements in  
276 the relevant pathways in the model. The complete growth suppression of the *pckA* mutant was

277 not observed in the model because multiple other routes for the chemical conversion between  
278 phosphoenol pyruvate and oxaloacetate *i.e.*, enolase (*eno*), phosphoshikimate 1-  
279 carboxyvinyltransferase (*aroA*) etc. are present in the model. The deletion of *ackA* gene also did  
280 not show severe growth inhibition because acetate could be generated via several routes in  
281 addition to the Pta-AckA pathway, specially *pdhABCD*, *aldA*, or *adhE*. The *gudB* mutant did not  
282 appear to be an essential gene in the model simulation because other genes including D-alanine  
283 transaminase (*dat*) and aspartate transaminase (*aspA*) could convert glutamate to alpha-  
284 ketoglutarate. However, it has been previously shown that the uptake of L-alanine in bacteria can  
285 be kinetically limited<sup>56</sup>. Hence, a tighter constraint on alanine uptake was imposed in the model,  
286 which resulted in a correct prediction of the essentiality of the *gudB* gene. The essentiality of  
287 *sucC* and *sucA* genes was ensured in the model by rectifying the alternate pathway consisting of  
288 succinyldiaminopimelate transaminase (*dapE*) and tetrahydrodipicolinate succinylase (*dapD*). In  
289 addition to that, the TCA cycle reactions converting citrate to succinyl-CoA were constrained to  
290 allow flux towards the forward direction only. Two of the gaps in the histidine transport pathway  
291 and proline catabolism were filled during the refinement process to allow for utilization of these  
292 alternate carbon sources in the absence of glucose. Ornithine-putrescine antiport, lactate  
293 dehydrogenase (ferricytochrome), malic enzyme (NADP), succinyldiaminopimelate  
294 transaminase etc. were removed from the model due to the lack of evidence of these  
295 functionalities in *S. aureus*. Upon these refinements, the model was able to correctly predict 24  
296 (out of 29) of the mutant phenotypes. The model refinements in the central metabolic pathway in  
297 terms of correction of reaction directionality, additions, and deletions are shown in Figure 3.

298

299 **Figure 3:** Refinements in the central metabolic pathway of the model *iSA840* showing correction of  
300 reaction directionality, additions, and deletions.

301

302 *Metabolite excretion profiles of mutants with altered carbon metabolism*

303 In addition to the model refinements mentioned in the preceding section, we determined the  
304 metabolite excretion profiles of eight mutants during exponential growth (Figure 4 and  
305 Supplementary Table 6) and compared them to the model predicted excretion patterns in both  
306 CDM and CDMG (CDM media with added glucose) media. The mutants considered were *pyc*  
307 (pyruvate carboxylase), *citZ* (citrate synthase), *sucA* (2-oxoglutarate dehydrogenase), *ackA*  
308 (acetate kinase), *gudB* (glutamate dehydrogenase), *ndhA* (NADH dehydrogenase), *menD*  
309 (menaquinone biosynthesis protein) and *atpA* (a subunit of ATPase). These mutants were  
310 selected for their potential in identifying carbon and nitrogen redirection pathways as they affect  
311 important metabolic pathways associated with central metabolism including glycolysis, TCA  
312 cycle, gluconeogenesis, Electron Transport Chain (ETC), cellular redox potential and overflow  
313 metabolism. In general, supplementation of glucose (CDMG) as the primary carbon source  
314 resulted in the excretion of acetate as the major byproduct in all mutants (Figure 4). In CDM, the  
315 *ackA*, *gudB*, *ndhA*, *atpA*, and *menD* mutants displayed delayed growth kinetics (data not shown).  
316 Although acetate remained a major byproduct of strains in CDM, this was due to amino acid  
317 deamination as evidenced by ammonia excretion (Figure 4). As carbon flux through the ATP-  
318 generating Pta-AckA pathway is significant in *S. aureus*, we also observed the excretion of  
319 pyruvate and redirection of carbon flux towards acetoin and  $\alpha$ -ketoglutarate in the *ackA* mutant  
320 (Figure 4). Mutations that affected respiration (*ndhA* and *menD*) of *S. aureus* resulted in  
321 increased levels of lactate production to maintain cellular redox when grown in CDMG (Figure  
322 4). The disruption of ATP production due to mutation of *atpA* was offset by increased acetate  
323 production and glucose consumption. The increased flux of glucose through the Pta-AckA

324 pathway to generate acetate likely compensated for the decrease in ATP production due to a  
325 faulty ATPase.

326

327 **Figure 4:** Metabolite excretion profile of multiple *S. aureus* mutants with altered carbon and  
328 nitrogen metabolism.

329

330 The comparison of experimental results and model predictions revealed multiple inconsistencies  
331 that motivated an extensive search for additional metabolic regulations in *S. aureus* in different  
332 media types. The full list of regulations can be found in Supplementary Table 7. A major  
333 regulatory system that was incorporated in the model was the carbon catabolite repression, which  
334 is a well-studied global regulatory process in low-GC Gram-positive bacteria in the presence of a  
335 preferred carbon source that induces the repression of genes involved in the metabolism of  
336 alternative carbon sources<sup>30</sup>. CcpA, the carbon catabolite control protein, is known to repress  
337 genes involved in the utilization of amino acids as alternative carbon sources in the presence of  
338 glucose<sup>38</sup>. In addition, SrrAB and Rex-dependent transcriptional regulation are prominent driving  
339 forces of metabolic flux through respiratory metabolism that was integrated into the model.  
340 Furthermore, mutant-specific repression of respiration, histidine and ornithine metabolism, and  
341 pyruvate metabolism were imposed on the model for the *menD* mutant. For each of the mutants,  
342 the incorporation of these regulations resulted in a deviation of the metabolic flux space (defined  
343 as the range between the minimum and maximum flux through reactions, see Methods section  
344 for details) compared to the wild type, as illustrated in Figure 5.

345

346 **Figure 5:** Shifts in flux space for eight mutants in the central carbon and nitrogen metabolic pathway.  
347 Every row in the table (inset) denotes a reaction as identified in the pathway map. The relative shifts  
348 compared to the wild type flux space are color-coded according to the legend in the figure.  
349  
350 Among the eight mutants, the model-predicted excretion patterns for acetate and lactate in *sucA*  
351 and *ackA* mutants agreed with the experimental results of decreased excretion in CDMG media,  
352 compared to the wild type strain. In CDM media, while no significant change in lactate excretion  
353 was observed, acetate excretion was decreased in the *ackA* mutant compared to the wild-type  
354 strain, due to inactivation of the Pta-AckA pathway. On the other hand, the *sucA* mutant in CDM  
355 media showed increased production of acetate due to increased flux space in the Pta-AckA  
356 pathway (see Figure 5). The Pta-AckA pathway is known to supply a major portion of the ATP  
357 required for growth<sup>27</sup>. With the *atpA* gene turned off in the model Pta-AckA pathway supplied  
358 most of the ATP demand, which increased the acetate production in CDMG media for the *atpA*  
359 mutant compared to the wild-type. However, in CDM media, the model could not sustain the  
360 ATP maintenance demand of the *atpA* mutant and therefore, did not produce any acetate. In  
361 CDMG media, the model-predicted excretion profile for urea in all of the mutants matched with  
362 the experimental observations. In CDM media, the model predictions of higher urea excretion  
363 compared to the wild-type strain agreed with the experimental observations for *pyc*, *gudB*, *ndhA*,  
364 and *menD* mutants. Similar to the experimental results, excretion of ammonia was predicted by  
365 the model in all mutants when glucose was absent (CDM media). These correct predictions can  
366 be attributed to the deamination of the amino acids consumed in CDM media when the cell  
367 adapts to amino acids due to CcpA-mediated control of amino acid metabolism.  
368



369 The incorporation of regulatory information improved the predictive capabilities of other  
370 mutants. For example, incorporation of regulation based on the Rex and SrrAB repressors' effect  
371 on central carbon metabolism allowed the model to correctly simulate the oxygen deprivation in  
372 the model, which, in turn, resulted in correct predictions of decreased acetate excretion by the  
373 *ndhA* mutant in both CDM and CDMG media. Rex and SrrAB-mediated repression of pyruvate  
374 formate lyase (PFLr), alcohol dehydrogenase (ACALD, ALDD2x) and other pathways  
375 downstream of pyruvate shifted carbon flux away from the acetate production. At the same time,  
376 the flux space for lactate dehydrogenase (LDH) widened, which allowed for more lactate  
377 excretion in the CDMG media. In the *menD* mutant, mutant-specific regulation information from  
378 Kohler *et al*<sup>37</sup> resulted in the correct prediction of lactate and acetate excretion. A mutation in  
379 *menD* or any other gene in the menaquinone biosynthesis pathway resulted in weakened  
380 respiratory functions and emulated anaerobic condition in the cell, which in turn caused a  
381 significant increase in the excretion of lactate in CDMG media. However, although the  
382 respiratory functions were downregulated in CDM media (apparent from the shrinkage of the  
383 flux space), there was no change in acetate excretion compared to the wild type strain. In CDMG  
384 media, the conversion of pyruvate to oxaloacetate by pyruvate carboxylase was not active in the  
385 wild type model. A small amount of phosphoenol pyruvate was converted to oxaloacetate (via  
386 PEPC), which was then used in the conversion of glutamate to aspartate. However, since no  
387 convincing evidence for phosphoenol pyruvate carboxylase was found in *S. aureus*, PEPC was  
388 removed. This refinement shifted carbon flux through pyruvate carboxylase in the wild type  
389 model and also resulted in correct model prediction of acetate excretion in CDMG media when  
390 pyruvate carboxylase was turned off.

391

392 While the incorporation of the CcpA, Rex and SrrAB regulations was critical in capturing the  
393 physiological behavior of *S. aureus* by the model, it should be noted that there are still gaps in  
394 our knowledge about the quantitative repression effect on the reaction fluxes in the presence of  
395 these regulators. For example, in CDMG media, ammonia production was not predicted in the  
396 *menD*, *atpA*, and *sucA* mutants by the model, which was observed experimentally. However,  
397 upon further investigation, it was observed that relaxing the repressions of reaction fluxes that  
398 were imposed on the model due to CcpA, Rex, and SrrAB regulators, the discrepancies were  
399 removed. In CDMG media, the *citZ* mutant correctly predicted the excretion pattern of acetate,  
400 because with the reduced flux space for the TCA cycle reactions, more carbon could be directed  
401 to the Pta-AckA pathway. However, in the CDM media, when amino acids were the primary  
402 source of carbon, deletion of the *citZ* gene did not have any effect on the model predicted flux  
403 space in the Pta-AckA pathway. In the *pyc* mutant, carbon flux to oxaloacetate was directed  
404 through malate dehydrogenase (MDH3) in the model, which involved the consumption of  
405 menaquinone produced by cytochrome oxidase BD. When the *pyc* gene was active, the same  
406 conversion was mediated through malic enzyme (ME1) and the pyruvate carboxylase (PC).  
407 However, since the model could accommodate the metabolic shift in both the wild-type and *pyc*  
408 mutant, no change in the excretion rate of acetate or lactate was observed. Also, while the CcpA  
409 repression was active, the deletion of the *gudB* gene in the model did not have any effect on the  
410 lactate and acetate excretion profiles in CDMG media. In CDM media, the model prediction for  
411 no lactate production was consistent with experimental observations but still no effect was  
412 observed on acetate production. Also, the model predicted a lower urea production rate in the  
413 *atpA* mutant compared to the wild-type strain, while it was higher in our experiments. Also, no  
414 urea excretion was observed in the *citZ* mutant in our experiments but model predicted urea

415 excretion at the same rate as the wild-type strain. The reason for these inconsistencies could be  
416 the lack of a complete understanding of the regulatory processes that affects the relationship  
417 between amino acid catabolism, urea cycle, TCA cycle and pyruvate metabolism. These  
418 inconsistencies warrant further investigation into CcpA-mediated metabolic control.

419

#### 420 *Estimation of carbon catabolism capacity of the model*

421 In order to further test the accuracy of the model, the growth predictive capability of the model  
422 was validated against a recent study of carbon source utilization by *S. aureus* strain USA300-  
423 TCH1516 by Seif *et al.*<sup>21</sup>. Out of the 69 carbon sources tested, the authors observed growth on 53  
424 metabolites and no growth on 16 metabolites in their BIOLOG experiment. Our model correctly  
425 predicted growth on 41 and no-growth on 12 of the carbon sources, and falsely predicted growth  
426 on four and no-growth on 12 carbon sources (see Supplementary Table 8 for details). In  
427 comparison, *iYS854* correctly predicted growth on 42 and no-growth on 5 of the carbon sources,  
428 and falsely predicted growth on 11 and no-growth on 11 carbon sources. Overall, our model  
429 achieved a specificity of 75%, a precision of 91%, and an accuracy of 77%, which in general are  
430 either at par with or better than previously developed models<sup>21</sup> and further demonstrates the  
431 improved predictive capability of this new model.

432

## 433 **Discussions**

434 In the current study, an updated and comprehensive genome-scale metabolic model of the  
435 methicillin-resistant human pathogen *S. aureus* USA300\_FPR3757 was reconstructed from the  
436 previous strain specific models<sup>19-21</sup>, amended using annotations based on KEGG database<sup>39</sup>, and  
437 refined based on published and new experimental results. Reactions were examined and fixed to

438 ensure chemical and charge balance and thermodynamic consistencies. The extensive manual  
439 curation performed on the preliminary reconstruction resulted in improved prediction capabilities  
440 and successful capture of experimentally observed metabolic traits. All these demonstrate the  
441 necessity of exhaustive manual scrutiny and rectification of automated reconstructions. The  
442 growth and no-growth analysis and the resolution of inconsistencies between *in silico* growth  
443 predictions and *in vivo* results using the Growmatch algorithm<sup>36,57</sup> reinforces the importance of  
444 the iterative procedure of model refinement using experimental observations. Further  
445 experimental results from mutant growth and metabolite excretion studies enabled high-  
446 resolution model refinements to further enhance the predictive capabilities of the model. The  
447 final genome-scale metabolic reconstruction (*i*SA840) is therefore a product of the series of  
448 automated and manual curation steps.

449  
450 Our growth evaluation experiment revealed varying degrees of growth inhibition of the NTML  
451 mutants compared to the wild type strain and identified subtle disagreements in gene essentiality  
452 predictions of other studies<sup>18,48-52</sup>. Therefore, the true set of essential genes required further  
453 scrutiny, which is why, as a conservative estimate, we used a consensus set of essential genes by  
454 utilizing the existing knowledge base and our own experimental findings (more details in  
455 Supplementary Information 1). Moreover, several mutants compromised in growth could be  
456 found in all the different methods, which did not appear to inhibit growth significantly during  
457 model simulations. Instead, the model either predicted growth at full capacity or became  
458 completely growth-inhibited. This phenomenon suggests that the model has degeneracy in the  
459 flux space that may compensate for lost functionality by redirecting or shifting metabolic fluxes.  
460 This issue calls for a more rigorous study of the regulatory influences and necessitates further

461 future studies in enzymatic efficiencies and kinetics associated with important metabolic  
462 pathways.

463

464 The growth phenotyping studies of mutations in the amino acid catabolic pathway<sup>29</sup> revealed  
465 shifts in *S. aureus* metabolism in the absence of a preferred carbon source and elucidated the  
466 extent of carbon catabolic repression, which allowed us to make necessary amendments to the  
467 model in terms of correction of reaction directionality, removal and addition of reactions, and  
468 specifying cofactor utilization across the central metabolic pathway (see Figure 3 for details).

469 The change in media components (CDM vs. CDMG) resulted in a significant redistribution of  
470 metabolic flux in the model, as was evident from the shifts in flux space for different mutants in  
471 the carbon and nitrogen metabolic pathways. These shifts predicted how inactivation and/or  
472 repression of TCA cycle, respiration, electron transport and ATP generation could impact the  
473 cellular redox balance, metabolite production, and fitness. While the model predictions for  
474 acetate and lactate production in the *ackA* and *sucA* mutants and ammonia and urea production in  
475 *ackA*, *pyc*, *gudB*, *ndhA*, and *menD* mutants matched with experimental results, other mutants  
476 showed deviations in their metabolite excretion behavior. The prediction capability of the model  
477 was improved upon the addition of regulatory information obtained from existing ‘omics’  
478 datasets<sup>30,37,38</sup>. For example, incorporation of Rex and SrrAB regulation caused repression on  
479 pyruvate metabolism and alcohol dehydrogenase pathways, which resulted in correct predictions  
480 of acetate excretion by the *ndhA* mutant in both CDM and CDMG media, and by the *citZ* and *pyc*  
481 mutants in CDMG media. Moreover, imposing mutant-specific repressions was critical to  
482 achieving predictive results for the acetate and lactate excretion in the *menD* mutant and  
483 ammonia and urea excretion in the *atpA* mutant. However, the current knowledge of the

484 regulatory landscape in *S. aureus* is not sufficient to explain some of the inconsistent metabolite  
485 production trends in the remainder of the mutants, thus, warranting the need for further  
486 investigation.

487

488 *S. aureus* remains a significant threat to human health, which drives a growing number of studies  
489 towards understanding how staphylococcal metabolism relates to antibiotic resistance and  
490 pathogenesis. Very few studies have addressed these interrelationships from a systems biology  
491 perspective, which requires a predictive *in silico* metabolic model capable of capturing the  
492 biochemical features of the pathogen. This work addresses these gaps through the development  
493 of a detailed metabolic model informed not only from existing resources, such as the NTML, *in*  
494 *silico* genome sequences, annotation databases, and theoretical metabolic stoichiometry but also  
495 from our own experimental studies on mutant fitness, gene essentiality, and metabolite excretion  
496 profile. The results presented in this work demonstrate the predictive capacity of the new  
497 genome-scale metabolic reconstruction of *S. aureus* USA300\_FPR3757, *iSA840*, in different  
498 environments, utilizing different substrates, and with perturbed genetic contents, which paves the  
499 way for a mechanistic understanding of *S. aureus* metabolism. This latest genome-scale model of  
500 *S. aureus* demonstrates high performance in capturing gene essentiality, mutant phenotype and  
501 substrate utilization behavior observed in experiments. However, the accuracy and prediction  
502 capability, as well as the ability to generate model-based drug-target discoveries, can be further  
503 enhanced by incorporating extensively vetted flux measurements, quantitative proteomics, and  
504 kinetic measurements of metabolic intermediates. The development of a more accurate systems-  
505 level metabolic model for *S. aureus* will have a tremendous impact on future scientific  
506 discoveries and will be a valuable resource shared among the staphylococcal research

507 community for the identification and implementation of intervention strategies that are  
508 successful against a wide range of pathogenic strains.

509

## 510 **Methods**

### 511 **Preliminary model reconstruction and curation**

512 *Preliminary model and flux balance analysis:* The primary reaction set was obtained from the  
513 genome-scale metabolic reconstruction of *S. aureus* USA300\_FPR3757 by Bosi *et al.*<sup>19</sup> and a  
514 recent model of strain JE2 by Seif *et al.*<sup>21</sup>. Reactions from the *S. aureus* N315 model *iSB619*<sup>20</sup>  
515 were checked against annotations of *S. aureus* USA300\_FPR3757 based on the KEGG  
516 database<sup>39</sup> and merged with the reaction set to get the preliminary model. Flux balance analysis  
517 (FBA)<sup>58-60</sup> was employed during model testing, validation, and analyzing flux distributions at  
518 different stages of the study. For performing FBA, the reconstruction was represented in a  
519 mathematical form of stoichiometric coefficients (known as stoichiometric matrix or S-matrix),  
520 where each column represents a metabolite and each row signifies a particular reaction. In  
521 addition to the mass balance constraints<sup>61</sup>, environmental constraints based on nutrient  
522 availability, the relational constraint of reaction rates with concentrations of metabolites, and  
523 thermodynamic constraints were imposed as necessary. The effects of gene expressions were  
524 incorporated as regulatory constraints on the model as the cell adapted to change in media or  
525 gene knockouts<sup>62</sup>. The non-growth-associated ATP maintenance demand was estimated to be  
526 5.00 mmol/gDCW.hr in CDM media and 7.91 mmol/gDCW.hr in CDMG media in this study,  
527 according to the established protocol<sup>63</sup>.

528

529 *Rectification of reaction imbalances:* To ensure that each of the reactions in the model is  
530 chemically balanced, the metabolite formula and the stoichiometry of the reactions were checked  
531 against biochemical databases<sup>34,39,64,65</sup>. For balancing the reactions imbalanced in protons, the  
532 protonation state consistent with the reaction set in the preliminary model was checked and  
533 additions/deletions of one or multiple protons or water on either the reactant or the product side  
534 were performed. For the other elements, correct stoichiometry was incorporated into the S-  
535 matrix. Reaction with unspecified macromolecule formula were not rectified.

536

537 *Identification and elimination of thermodynamically Infeasible Cycles:* One of the limitations of  
538 constraint-based genome-scale models is that the mass balance constraints only describe the net  
539 accumulation or consumption of metabolites, without restricting the individual reaction fluxes.  
540 Therefore, they have an inherent tendency to ignore the loop law for electric circuits which states  
541 that there can be no flow through a closed loop in any network at steady state<sup>47</sup>. While  
542 biochemical conversion cycles like TCA cycle or urea cycle are ubiquitous in a metabolic  
543 network model, there can be cycles which do not have any net consumption or production of any  
544 metabolite. Therefore, the overall thermodynamic driving force of these cycles are zero,  
545 implying that no net flux can flow around these cycles<sup>47</sup>. It is important to identify and eliminate  
546 these Thermodynamically Infeasible Cycles (TICs) to achieve sensible and realistic metabolic  
547 flux distributions.

548

549 To identify Thermodynamically Infeasible Cycles in the model, all the nutrient uptakes to the  
550 cell were turned off and an optimization formulation called Flux Variability Analysis (FVA) was  
551 used<sup>66</sup>. FVA maximizes and minimizes each of the reaction fluxes subject to mass balance,



552 environmental, and any artificial (*i.e.*, biomass threshold) constraints<sup>66</sup>. The reaction fluxes  
553 which hit either the lower bounds or upper bounds are defined as unbounded reactions and were  
554 grouped as a linear combination of the null basis of their stoichiometric matrix. These groups are  
555 indicative of possible thermodynamically infeasible cycles. To eliminate/destroy the cycles,  
556 duplicate reactions were removed, lumped reaction were turned off or reactions were selectively  
557 turned on/off based on available cofactor specificity information (see Supplementary Information  
558 1 for details).

559

### 560 **Evaluation of growth profiles of mutants in NTML**

561 Pre-cultures of wild-type and isogenic transposon mutant strains were grown overnight  
562 aerobically in 384-well plates containing 100  $\mu$ L of Tryptic Soy Broth (TSB)/ well. The  
563 overnight cultures (1  $\mu$ L) were seeded into a fresh 384-well plate containing TSB (100  $\mu$ L/ well)  
564 using a solid 384 pin tool (V & P Scientific) and cultured for 24 h at 37°C under maximum  
565 agitation in a TECAN microplate reader. Growth was monitored by recording the optical density  
566 (OD<sub>600</sub>) of cultures for 24 h at 30-minute intervals. The area under the growth curve (AUC) was  
567 calculated as a measure of growth for each strain and used for comparative analyses.

568

### 569 **Elimination of Growth and No-growth Inconsistencies between model predictions and** 570 **experimental data**

571 *Gene essentiality analyses:* Metabolic robustness of an organism in the event of genetic  
572 manipulations are attributed to the essentiality of the respective gene(s) under a specific nutrient  
573 medium or regulatory condition<sup>24</sup>. In any metabolic reconstruction, there are either missing  
574 necessary functionalities in the model or erroneous pathways present in the model, mainly due to

575 missing or wrong annotation information. To identify these inconsistencies in the model, *in silico*  
576 essential and non-essential genes were identified by turning off the reaction(s) catalyzed by the  
577 gene following the Boolean logic of the Gene-Protein-Reaction (GPR) relationships, and  
578 estimating growth as a result of the deletion. Isozymes (i.e., proteins/genes with an “OR”  
579 relationship) for essential reactions are not considered as essential, and for reaction catalyzed by  
580 protein with multiple subunits (i.e., proteins/genes with an “AND” relationship), each gene  
581 responsible for each subunit is considered essential. A mutant was classified as lethal if its  
582 growth rate is below the threshold of 10% of the wild type growth rate.

583

584 *In vivo* essential genes were curated from multiple sources<sup>18,48-52</sup>, as explained in detail in the  
585 Supplementary Text S1. Most of the essential genes were determined by randomly inserting  
586 transposons into *S. aureus* and excluding mutations that remained after growing the cells<sup>48,49,51</sup>.  
587 An adaptation of data from multiple sources using antisense RNA was also used to determine  
588 essential enzymes and thus essential genes through the Boolean relationships<sup>18,50,52</sup>. Genes  
589 reported to be essential in any sources were considered essential unless there was evidence  
590 suggesting otherwise<sup>18,48-52</sup>. There were three types of positive evidence. First, mutants obtained  
591 from Nebraska’s Transposon Mutant Library<sup>35,67</sup> were not considered essential unless it was  
592 found to be domain-essential<sup>48</sup>. This is because the transposon may have inserted in a non-  
593 essential part of the gene, allowing a partially functional protein to be formed. Second, if the  
594 gene was found to be essential at only 43<sup>0</sup>C, then it is evident that the gene was incorrectly found  
595 to be essential in literature because of a high-temperature plasmid curing step in the processes  
596 used in the other literature sources<sup>48</sup>. Third, if the gene was found to be essential using a  
597 promoterless transposon insert, but not with promoter-containing methodologies, then the gene is

598 upstream of an essential gene, and other sources found it to be essential due to polar effects that  
599 disrupt expression<sup>48</sup>. The step-by-step methodology used in determining core essential gene set  
600 is illustrated in Supplementary Figure S4.

601

602 Out of the consensus set of the essential genes, 167 metabolic genes that are present in the  
603 *iSA840* metabolic model were considered for further model refinements. The results of the *in*  
604 *silico* growth estimation were compared with these experimental evidences, and the genes were  
605 classified based on the matches and mismatches between *in silico* and *in vivo* results. Correct  
606 model predictions for non-essential and essential genes are denoted by GG and NGNG, while  
607 wrong model predictions for non-essential and essential genes are denoted by NGG and GNG,  
608 respectively. GNG inconsistencies imply that the metabolic model erroneously contains reactions  
609 that complement for the lost gene function. In contrast, NGG inconsistencies are generally  
610 indicative of missing or poor annotations in the model.

611

612 *Using GrowMatch to resolve inconsistencies:* To resolve the growth and no-growth  
613 inconsistencies in the model, an automated procedure called GrowMatch was used<sup>36</sup>.  
614 GrowMatch tries to reconcile GNG predictions by suppressing spurious functionalities that were  
615 mistakenly included in the model and NGG predictions by adding missing functionalities to the  
616 model while maintaining the already identified correct growth and no-growth predictions<sup>36</sup>.  
617 Every suggested GrowMatch modification was filtered for the resolution of conflict following  
618 the procedure of Henry *et al.* in 2009<sup>43</sup>. A detailed explanation of these cases can be found in the  
619 Supplementary Table 5.

620

### 621 **Determination of metabolite excretion profiles of mutants**

622 To determine the metabolite excretion profile of various strains, cell-free culture supernatants  
623 were analyzed by HPLC for multiple weak acids, acetoin, and sugars as previously described.  
624 Briefly, the analysis was performed isocratically at 0.5 mL/min and 65°C using a Biorad Aminex  
625 HPX-87H cation exchange column with 0.13N H<sub>2</sub>SO<sub>4</sub> as the mobile phase. The peaks  
626 corresponding to various metabolites were identified by their retention time obtained by using  
627 genuine standards. Absolute concentrations were determined from calibration curves specific to  
628 each metabolite. Ammonia and urea were measured using a kit (R-biopharm) according to the  
629 manufacturer's protocol.

630

### 631 **Incorporation of regulation in the model**

632 Regulation information for *S. aureus* in terms of differential expression of genes or high/low  
633 abundance of the corresponding proteins were accumulated from multiple sources as listed in  
634 Supplementary Table 7. Gene-Protein-Reaction (GPR) Boolean relationships for each of the  
635 genes were used to determine the corresponding reactions to be regulated in model simulations in  
636 different conditions. If a reaction is catalyzed by multiple isozymes, the reaction was only  
637 suppressed if all of the isozymes were downregulated in a certain condition. For a reaction  
638 catalyzed by multiple subunit proteins, it was suppressed if any of the genes responsible for a  
639 subunit was downregulated. For aerobic vs. anaerobic simulations in the model, the lower bound  
640 and upper bound for the regulated reactions were set to zero. For CcpA, SrrAB, and Rex  
641 repression, the allowable flux ranges were limited to 50% of their wild-type flux values. For the  
642 reactions suppressed in *menD* mutant, a similar flux limitation was imposed.

643

## 644 **Data Availability**

645 All data generated or analyzed during this study are included in this published article and its  
646 supplementary information files.

647

## 648 **Competing Interests**

649 The authors declare no competing interest for the presented work.

650

## 651 **Contributions**

652 R.S., V.C.T., P.D.F. and K.W.B. conceived the study. R.S. and V.C.T supervised the study.  
653 V.C.T., J.S.A, A.A.A and C.Z. performed and analyzed the *in vivo* studies. M.M.I performed the  
654 *in silico* experiments and analyses. M.V.B. and M.M.I. developed the required software  
655 programs, models, and graphics. M.M.I, M.V.B., R.S., and V.C.T. wrote the manuscript. All  
656 authors have reviewed and approved the submission of the manuscript.

657

## 658 **Funding**

659 This work was supported by the Nebraska Systems Science Initiative Seed Grant [WBS# 21-  
660 3209-0013] to R.S., V.C.T, K.W.B., and P.D.F.; NIH/NIAID P01AI083211 to K.W.B. and  
661 P.D.F; NIH/NIAID R01AI125588 to V.C.T.

## 662 **Supplementary Information**

663 **Supplementary Information 1:** Strategies for fixing thermodynamically infeasible cycles,  
664 consensus of *in vivo* gene essentiality information, and details of GrowMatch procedure and  
665 results.

666 **Supplementary Table 1:** Growth medium definition.

667 **Supplementary Table 2:** Fixed reactions imbalanced in carbon, hydrogen and oxygen.

668 **Supplementary Table 3:** All the reactions turned off or directionality changed or removed as a  
669 duplicate during model curation steps.

670 **Supplementary Table 4:** NTML mutant growth data and statistical analysis.

671 **Supplementary Table 5:** Gene essentiality information, comparison of model and experimental  
672 essentiality results, GNG tables, Growmatch results, and rejected Growmatch suggestions.

673

674 **Supplementary Table 6:** Metablite excretion profiles by mutants in CDM and CDMG media.

675

676 **Supplementary Table 7:** Regulations and repressions imposed on the model.

677

678 **Supplementary Table 8:** Model predictions on utilization of different carbon sources and  
679 comparison with BIOLOG experimental results.

680

681 **Supplementary Data 1:** The *S. aureus* USA300\_FPR3757 metabolic model in systems biology  
682 markup language format.

683

684 Supplementary information is available at NPJ Systems Biology and Applications' website.

685

## 686 **References**

687

688 1 Klevens, R. M. *et al.* Invasive methicillin-resistant *Staphylococcus aureus* infections in the United  
689 States. *JAMA : the journal of the American Medical Association* **298**, 1763-1771,  
690 doi:10.1001/jama.298.15.1763 (2007).

691 2 Kluytmans, J., van Belkum, A. & Verbrugh, H. Nasal carriage of *Staphylococcus aureus*:  
692 epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev* **10**, 505-520  
693 (1997).

694 3 Diekema, D. J. *et al.* Survey of infections due to *Staphylococcus* species: frequency of occurrence  
695 and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America,  
696 Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program,  
697 1997-1999. *Clinical infectious diseases : an official publication of the Infectious Diseases Society*  
698 *of America* **32 Suppl 2**, S114-132, doi:10.1086/320184 (2001).

699 4 Simons, H. & Alcabes, P. A model for surveillance of methicillin-resistant *Staphylococcus*  
700 *aureus*. *Public Health Rep* **123**, 21-29 (2008).

701 5 Wertheim, H. F. *et al.* The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet*  
702 *Infect Dis* **5**, 751-762, doi:10.1016/S1473-3099(05)70295-4 (2005).

703 6 Chaudhari, S. S. *et al.* Nitrite Derived from Endogenous Bacterial Nitric Oxide Synthase Activity  
704 Promotes Aerobic Respiration. *Mbio* **8**, doi:10.1128/mBio.00887-17 (2017).

- 705 7 Gusarov, I., Shatalin, K., Starodubtseva, M. & Nudler, E. Endogenous nitric oxide protects  
706 bacteria against a wide spectrum of antibiotics. *Science* **325**, 1380-1384,  
707 doi:10.1126/science.1175439 (2009).
- 708 8 van Sorge, N. M. *et al.* Methicillin-resistant *Staphylococcus aureus* bacterial nitric-oxide synthase  
709 affects antibiotic sensitivity and skin abscess development. *J Biol Chem* **288**, 6417-6426,  
710 doi:10.1074/jbc.M112.448738 (2013).
- 711 9 Sapp, A. M. *et al.* Contribution of the *nos-pdt* operon to virulence phenotypes in methicillin-  
712 sensitive *Staphylococcus aureus*. *PloS one* **9**, e108868, doi:10.1371/journal.pone.0108868 (2014).
- 713 10 Richardson, A. R., Libby, S. J. & Fang, F. C. A nitric oxide-inducible lactate dehydrogenase  
714 enables *Staphylococcus aureus* to resist innate immunity. *Science* **319**, 1672-1676,  
715 doi:10.1126/science.1155207 (2008).
- 716 11 Marshall, D. D., Sadykov, M. R., Thomas, V. C., Bayles, K. W. & Powers, R. Redox Imbalance  
717 Underlies the Fitness Defect Associated with Inactivation of the Pta-AckA Pathway in  
718 *Staphylococcus aureus*. *Journal of proteome research* **15**, 1205-1212,  
719 doi:10.1021/acs.jproteome.5b01089 (2016).
- 720 12 Raskevicius, V. *et al.* Genome scale metabolic models as tools for drug design and personalized  
721 medicine. *PloS one* **13**, e0190636, doi:10.1371/journal.pone.0190636 (2018).
- 722 13 Bordel, S. Constraint based modeling of metabolism allows finding metabolic cancer hallmarks  
723 and identifying personalized therapeutic windows. *Oncotarget* **9**, 19716-19729,  
724 doi:10.18632/oncotarget.24805 (2018).
- 725 14 Zhang, C. & Hua, Q. Applications of Genome-Scale Metabolic Models in Biotechnology and  
726 Systems Medicine. *Frontiers in physiology* **6**, 413, doi:10.3389/fphys.2015.00413 (2015).
- 727 15 Dunphy, L. J. & Papin, J. A. Biomedical applications of genome-scale metabolic network  
728 reconstructions of human pathogens. *Curr Opin Biotechnol* **51**, 70-79,  
729 doi:10.1016/j.copbio.2017.11.014 (2017).
- 730 16 Agren, R. *et al.* Identification of anticancer drugs for hepatocellular carcinoma through  
731 personalized genome-scale metabolic modeling. *Mol Syst Biol* **10**, 721, doi:10.1002/msb.145122  
732 (2014).



- 733 17 Mienda, B. S., Salihu, R., Adamu, A. & Idris, S. Genome-scale metabolic models as platforms for  
734 identification of novel genes as antimicrobial drug targets. *Future Microbiol* **13**, 455-467,  
735 doi:10.2217/fmb-2017-0195 (2018).
- 736 18 Lee, D. S. *et al.* Comparative genome-scale metabolic reconstruction and flux balance analysis of  
737 multiple *Staphylococcus aureus* genomes identify novel antimicrobial drug targets. *J Bacteriol*  
738 **191**, 4015-4024, doi:10.1128/JB.01743-08 (2009).
- 739 19 Bosi, E. *et al.* Comparative genome-scale modelling of *Staphylococcus aureus* strains identifies  
740 strain-specific metabolic capabilities linked to pathogenicity. *Proc Natl Acad Sci U S A* **113**,  
741 E3801-3809, doi:10.1073/pnas.1523199113 (2016).
- 742 20 Becker, S. A. & Palsson, B. O. Genome-scale reconstruction of the metabolic network in  
743 *Staphylococcus aureus* N315: an initial draft to the two-dimensional annotation. *BMC*  
744 *microbiology* **5**, 8, doi:10.1186/1471-2180-5-8 (2005).
- 745 21 Seif, Y. *et al.* A computational knowledge-base elucidates the response of *Staphylococcus aureus*  
746 to different media types. *PLoS computational biology* **15**, e1006644,  
747 doi:10.1371/journal.pcbi.1006644 (2019).
- 748 22 Heinemann, M., Kummel, A., Ruinatscha, R. & Panke, S. In silico genome-scale reconstruction  
749 and validation of the *Staphylococcus aureus* metabolic network. *Biotechnology and*  
750 *bioengineering* **92**, 850-864, doi:10.1002/bit.20663 (2005).
- 751 23 Joyce, A. R. & Palsson, B. O. Predicting gene essentiality using genome-scale in silico models.  
752 *Methods Mol Biol* **416**, 433-457, doi:10.1007/978-1-59745-321-9\_30 (2008).
- 753 24 Suthers, P. F., Zomorodi, A. & Maranas, C. D. Genome-scale gene/reaction essentiality and  
754 synthetic lethality analysis. *Mol Syst Biol* **5**, 301, doi:10.1038/msb.2009.56 (2009).
- 755 25 Kim, T. Y., Kim, H. U. & Lee, S. Y. Metabolite-centric approaches for the discovery of  
756 antibacterials using genome-scale metabolic networks. *Metab Eng* **12**, 105-111,  
757 doi:10.1016/j.ymben.2009.05.004 (2010).
- 758 26 Schiebel, J. *et al.* *Staphylococcus aureus* FabI: inhibition, substrate recognition, and potential  
759 implications for in vivo essentiality. *Structure* **20**, 802-813, doi:10.1016/j.str.2012.03.013 (2012).

- 760 27 Sadykov, M. R. *et al.* Inactivation of the Pta-AckA pathway causes cell death in *Staphylococcus*  
761 *aureus*. *J Bacteriol* **195**, 3035-3044, doi:10.1128/JB.00042-13 (2013).
- 762 28 Harper, L. *et al.* *Staphylococcus aureus* Responds to the Central Metabolite Pyruvate To Regulate  
763 Virulence. *Mbio* **9**, doi:10.1128/mBio.02272-17 (2018).
- 764 29 Halsey, C. R. *et al.* Amino Acid Catabolism in *Staphylococcus aureus* and the Function of  
765 Carbon Catabolite Repression. *Mbio* **8**, doi:10.1128/mBio.01434-16 (2017).
- 766 30 Leiba, J. *et al.* A novel mode of regulation of the *Staphylococcus aureus* catabolite control protein  
767 A (CcpA) mediated by Stk1 protein phosphorylation. *J Biol Chem* **287**, 43607-43619,  
768 doi:10.1074/jbc.M112.418913 (2012).
- 769 31 Thomas, V. C. *et al.* A central role for carbon-overflow pathways in the modulation of bacterial  
770 cell death. *PLoS Pathog* **10**, e1004205, doi:10.1371/journal.ppat.1004205 (2014).
- 771 32 Richardson, A. R. Virulence and Metabolism. *Microbiol Spectr* **7**,  
772 doi:10.1128/microbiolspec.GPP3-0011-2018 (2019).
- 773 33 Arkin, A. P. *et al.* KBase: The United States Department of Energy Systems Biology  
774 Knowledgebase. *Nature biotechnology* **36**, 566-569, doi:10.1038/nbt.4163 (2018).
- 775 34 Henry, C. S. *et al.* High-throughput generation, optimization and analysis of genome-scale  
776 metabolic models. *Nature biotechnology* **28**, 977-982, doi:10.1038/nbt.1672 (2010).
- 777 35 Fey, P. D. *et al.* A genetic resource for rapid and comprehensive phenotype screening of  
778 nonessential *Staphylococcus aureus* genes. *Mbio* **4**, e00537-00512, doi:10.1128/mBio.00537-12  
779 (2013).
- 780 36 Kumar, V. S. & Maranas, C. D. GrowMatch: an automated method for reconciling in silico/in  
781 vivo growth predictions. *PLoS computational biology* **5**, e1000308,  
782 doi:10.1371/journal.pcbi.1000308 (2009).
- 783 37 Kohler, C. *et al.* A defect in menadione biosynthesis induces global changes in gene expression in  
784 *Staphylococcus aureus*. *J Bacteriol* **190**, 6351-6364, doi:10.1128/JB.00505-08 (2008).
- 785 38 Seidl, K. *et al.* Effect of a glucose impulse on the CcpA regulon in *Staphylococcus aureus*. *BMC*  
786 *microbiology* **9**, 95, doi:10.1186/1471-2180-9-95 (2009).

- 787 39 Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic acids*  
788 *research* **28**, 27-30, doi:DOI 10.1093/nar/28.1.27 (2000).
- 789 40 Coordinators, N. R. Database resources of the National Center for Biotechnology Information.  
790 *Nucleic acids research*, doi:10.1093/nar/gkx1095 (2017).
- 791 41 UniProt, C. The Universal Protein Resource (UniProt). *Nucleic acids research* **35**, D193-197,  
792 doi:10.1093/nar/gkl929 (2007).
- 793 42 Fuchs, S. *et al.* AureoWiki The repository of the Staphylococcus aureus research and annotation  
794 community. *Int J Med Microbiol* **308**, 558-568, doi:10.1016/j.ijmm.2017.11.011 (2018).
- 795 43 Henry, C. S., Zinner, J. F., Cohoon, M. P. & Stevens, R. L. iBsu1103: a new genome-scale  
796 metabolic model of Bacillus subtilis based on SEED annotations. *Genome Biol* **10**, R69,  
797 doi:10.1186/gb-2009-10-6-r69 (2009).
- 798 44 Feist, A. M. *et al.* A genome-scale metabolic reconstruction for Escherichia coli K-12 MG1655  
799 that accounts for 1260 ORFs and thermodynamic information. *Mol Syst Biol* **3**, 121,  
800 doi:10.1038/msb4100155 (2007).
- 801 45 Joshi, G. S., Spontak, J. S., Klapper, D. G. & Richardson, A. R. Arginine catabolic mobile  
802 element encoded speG abrogates the unique hypersensitivity of Staphylococcus aureus to  
803 exogenous polyamines. *Mol Microbiol* **82**, 9-20, doi:10.1111/j.1365-2958.2011.07809.x (2011).
- 804 46 Chan, S. H. J., Cai, J., Wang, L., Simons-Senftle, M. N. & Maranas, C. D. Standardizing biomass  
805 reactions and ensuring complete mass balance in genome-scale metabolic models. *Bioinformatics*  
806 **33**, 3603-3609, doi:10.1093/bioinformatics/btx453 (2017).
- 807 47 Schellenberger, J., Lewis, N. E. & Palsson, B. O. Elimination of thermodynamically infeasible  
808 loops in steady-state metabolic models. *Biophysical journal* **100**, 544-553,  
809 doi:10.1016/j.bpj.2010.12.3707 (2011).
- 810 48 Santiago, M. *et al.* A new platform for ultra-high density Staphylococcus aureus transposon  
811 libraries. *BMC Genomics* **16**, 252, doi:10.1186/s12864-015-1361-3 (2015).
- 812 49 Valentino, M. D. *et al.* Genes contributing to Staphylococcus aureus fitness in abscess- and  
813 infection-related ecologies. *Mbio* **5**, e01729-01714, doi:10.1128/mBio.01729-14 (2014).

- 814 50 Forsyth, R. A. *et al.* A genome-wide strategy for the identification of essential genes in  
815 Staphylococcus aureus. *Molecular Microbiology* **43**, 1387-1400, doi:DOI 10.1046/j.1365-  
816 2958.2002.02832.x (2002).
- 817 51 Chaudhuri, R. R. *et al.* Comprehensive identification of essential Staphylococcus aureus genes  
818 using Transposon-Mediated Differential Hybridisation (TMDH). *BMC Genomics* **10**, 291,  
819 doi:10.1186/1471-2164-10-291 (2009).
- 820 52 Ji, Y. D. *et al.* Identification of critical staphylococcal genes using conditional phenotypes  
821 generated by antisense RNA. *Science* **293**, 2266-2269, doi:DOI 10.1126/science.1063566 (2001).
- 822 53 Jayasekera, M. M., Saribas, A. S. & Viola, R. E. Enhancement of catalytic activity by gene  
823 truncation: activation of L-aspartase from Escherichia coli. *Biochemical and biophysical research*  
824 *communications* **238**, 411-414, doi:10.1006/bbrc.1997.7294 (1997).
- 825 54 Paulsen, J. & Hustedt, H. Extractive purification of aspartase from Escherichia coli K12. *Methods*  
826 *in enzymology* **228**, 590-599 (1994).
- 827 55 Whiteman, P., Marks, C. & Freese, E. The sodium effect of Bacillus subtilis growth on aspartate.  
828 *Journal of general microbiology* **119**, 493-504, doi:10.1099/00221287-119-2-493 (1980).
- 829 56 Piperno, J. R. & Oxender, D. L. Amino acid transport systems in Escherichia coli K-12. *J Biol*  
830 *Chem* **243**, 5914-5920 (1968).
- 831 57 Zomorodi, A. R. & Maranas, C. D. Improving the iMM904 S. cerevisiae metabolic model using  
832 essentiality and synthetic lethality data. *Bmc Syst Biol* **4**, 178, doi:10.1186/1752-0509-4-178  
833 (2010).
- 834 58 Varma, A. & Palsson, B. O. Metabolic Capabilities of Escherichia coli: I. Synthesis of  
835 Biosynthetic Precursors and Cofactors. *Journal of theoretical biology* **165**, 477-502,  
836 doi:<http://dx.doi.org/10.1006/jtbi.1993.1202> (1993).
- 837 59 Varma, A. & Palsson, B. O. Stoichiometric flux balance models quantitatively predict growth and  
838 metabolic by-product excretion in wild-type Escherichia coli W3110. *Appl Environ Microbiol* **60**,  
839 3724-3731 (1994).

- 840 60 Oberhardt, M. A., Chavali, A. K. & Papin, J. A. Flux balance analysis: interrogating genome-  
841 scale metabolic networks. *Methods Mol Biol* **500**, 61-80, doi:10.1007/978-1-59745-525-1\_3  
842 (2009).
- 843 61 Orth, J. D., Thiele, I. & Palsson, B. O. What is flux balance analysis? *Nat Biotech* **28**, 245-248,  
844 doi:<http://www.nature.com/nbt/journal/v28/n3/abs/nbt.1614.html#supplementary-information>  
845 (2010).
- 846 62 Terzer, M., Maynard, N. D., Covert, M. W. & Stelling, J. Genome-scale metabolic networks.  
847 *Wiley interdisciplinary reviews. Systems biology and medicine* **1**, 285-297, doi:10.1002/wsbm.37  
848 (2009).
- 849 63 Thiele, I. & Palsson, B. O. A protocol for generating a high-quality genome-scale metabolic  
850 reconstruction. *Nat Protoc* **5**, 93-121, doi:10.1038/nprot.2009.203 (2010).
- 851 64 Pence, H. E. & Williams, A. ChemSpider: An Online Chemical Information Resource. *J Chem*  
852 *Educ* **87**, 1123-1124, doi:10.1021/ed100697w (2010).
- 853 65 Schellenberger, J., Park, J. O., Conrad, T. M. & Palsson, B. O. BiGG: a Biochemical Genetic and  
854 Genomic knowledgebase of large scale metabolic reconstructions. *BMC bioinformatics* **11**, 213,  
855 doi:10.1186/1471-2105-11-213 (2010).
- 856 66 Mahadevan, R. & Schilling, C. H. The effects of alternate optimal solutions in constraint-based  
857 genome-scale metabolic models. *Metab Eng* **5**, doi:10.1016/j.ymben.2003.09.002 (2003).
- 858 67 Bae, T., Glass, E. M., Schneewind, O. & Missiakas, D. Generating a collection of insertion  
859 mutations in the *Staphylococcus aureus* genome using *bursa aurealis*. *Methods Mol Biol* **416**, 103-  
860 116, doi:10.1007/978-1-59745-321-9\_7 (2008).
- 861
- 862
- 863
- 864
- 865

866 **Figure legends**

867

868 **Figure 1:** (a) The schematic of the reconstruction and curation process for *iSA840*, (b) pathway  
869 distribution of metabolic functions, (c) overlap of functionalities, and (d) comparison of model  
870 statistics with recent *S. aureus* metabolic models.

871

872 **Figure 2:** GNG table (a) before and (b) after reconciliation of growth-no growth inconsistency by  
873 GrowMatch procedure. Specificity =  $\#NGNG/(\#NGNG + \#GNG)$ , sensitivity or true viable rate (TVR) =  
874  $\#GG/(\#GG + \#NGG)$  and false viable rate (FVR) =  $\#GNG/(\#GNG + \#NGNG)$ , (c) a case study of NGG  
875 inconsistency and the corresponding Growmatch solution, and (d) a case study of GNG inconsistency and  
876 the corresponding Growmatch solution.

877

878 **Figure 3:** Refinements in the central metabolic pathway of the model *iSA840* showing correction of  
879 reaction directionality, additions, and deletions.




880

881 **Figure 4:** Metabolite excretion profile of multiple *S. aureus* mutants with altered carbon and  
882 nitrogen metabolism.

883

884 **Figure 5:** Shifts in flux space for 8 mutants in the central carbon and nitrogen metabolic  
885 pathway. Every row in the table (inset) denotes a reaction as identified in the pathway map. The  
886 relative shifts compared to the wild type flux space are color-coded according to the legend in  
887 the figure.

888



**d**

	<i>iSB619</i>	<i>iSAUSA300_842</i>	<i>iYS854</i>	<i>iSA840</i>
<b>Genes</b>	619	842 (733 associated with reactions)	854	840
<b>Reactions</b>	640	1517	1440	1566
<b>Metabolites</b>	571	1431	1327	1442
<b>Imbalanced reactions</b> (excluding reactions with unspecified macromolecular formula)	-	490	-	0
<b>Blocked reactions</b>	108 (~17%)	784 (~52%)	428 (~30%)	553 (~35%)
<b>Unbounded reactions</b>	-	291 (~19%)	53 (~19%)	7 (~0.4%)

**a** Before Growmatch

		<i>In vivo</i>	
		G	NG
<i>In silico</i>	G	585	80
	NG	86	87

Specificity = 52.10 %

Sensitivity = 87.18 %

False Viability Rate (FVR) = 47.90 %

**b** After Growmatch


		<i>In vivo</i>	
		G	NG
<i>In silico</i>	G	597	66
	NG	74	101

Specificity = 60.48 %

Sensitivity = 88.97 %

False Viability Rate (FVR) = 39.52 %

**c**



**d**

